Company: VRCA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0000950170-25-107358
Chunk: 9

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part II, Item 6
Chunk 9
---
31

EXHIBIT INDEX 

     ExhibitNo.
      
     Description

     3.1 (1)
       
     Amended and Restated Certificate of Incorporation.

     3.2 (2)
      
     Certificate of Amendment of the Amended and Restated Certificate of Incorporation

     3.2 (3)
       
     Amended and Restated Bylaws.

     10.1 
      
     Sixth Amendment and Waiver to Credit Agreement dated as of June 10, 2025, by and between the Company and OrbiMed Royalty & Credit Opportunities IV, LP.

     10.2+^ 
      
     Second Amendment to Collaboration and License Agreement, dated as of June 27, 2025, by and between the Company and Torii Pharmaceuticals Co., Ltd. 

     31.1
       
     Certification of Chief Executive Officer and President (Principal Executive Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

     31.2
       
     Certification of Interim Chief Financial Officer (Interim Principal Financial Officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

     32.1*
       
     Certifications of Chief Executive Officer and President (Principal Executive Officer) and Interim Chief Financial Officer (Interim Principal Financial Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

     101.INS
      
     Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. 

     101.SCH
      
     Inline XBRL Taxonomy Extension Schema Document

     104
      
     Cover Page Interactive Data File (embedded within the Inline XBRL document)
    
    (1) Previously filed as Exhibit 3.3 to the Company’s Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018.(2) Previously filed as Exhibit 3.1 to the Company's Current Report on Form 8-K (File No. 001-38529), filed with the Securities and Exchange Commission on July 23, 2025. (